Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

android tablet pc

Home > Press > NanoViricides Presents FluCide™ Animal Study Data At Influenza Congress

Now Improved Substantially And Vastly Superior To Current Treatment

NanoViricides Presents FluCide™ Animal Study Data At Influenza Congress

West Haven, CT | Posted on November 24th, 2009

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced that Dr. Eugene Seymour, MD MPH, CEO of the Company, presented lifetime data from the recent FluCide™ animal study on November 19th at the Influenza Congress USA 2009 in Washington, DC.

These data clearly established that the new version of FluCide™ is superior to the older version. The data also showed extremely large survival lifetime improvement compared to an extended therapy using oseltamivir (Tamiflu® Roche).

Separately, Dr. Anil R. Diwan, President of the Company, presented a talk on November 18th at the Nano and Clean Tech 2009 Conference ( in New York City, held in conjunction and partnership with the Chem Show 2009.

Dr. Diwan gave a description of the nanomedicine technology on which the Company's product platform is based. He then went on to discuss the successful development of several drug candidates in a relatively short timeframe and with very small R&D expenditures that NanoViricides Inc. has been able to achieve. "Our achievements have clearly demonstrated that we can develop drug candidates against new virus targets very quickly," he said. He explained that the multi-point binding of a nanoviricide™, enabled by the underlying TheraCour® polymer, results in a nanoscale "velcro" or zipper-like effect. This allows the Company to employ virus-binding ligands with relatively low affinities successfully. "Other drug development approaches require discovery of antibodies or chemicals with very high affinities, sub-micromolar or better, which takes a lot of time and money," he said, adding, "In contrast, our technology allows us to use mimics of the natural and conserved binding sites of the viruses. This allows rapid development. Also, it means that a virus is far less likely to escape a nanoviricide compared to its escape rate against a highly specific drug discovered using a conventional methodology."

The recent animal study of FluCide was conducted using the same total lethality protocol employed in previous influenza studies by the Company. The new version of FluCide drug candidate extended the lifespan of lethally infected mice to 334±11 hrs (or 14 days) on average. In contrast, mice treated with an extended oseltamivir protocol survived for 193±3 hrs (or 8 days) on average. Control infected mice survived for only 121±2 hrs (or 5 days). FluCide was given as an IV injection, on alternate days, for five treatments. Oseltamivir was given as oral, twice daily, each at 20mg/kg through life (or 14 treatments). Previously, oseltamivir given using the customary protocol of oral, twice daily, each at 20mg/kg for 4 days (8 treatments), has produced a survival time of 151±1 hrs (or 6.3 days) in this model. Several additional parameters have been evaluated in this study. The Company expects to analyze the data from these additional parameters as they are received in the near future.

The Company believes that the lifetime data demonstrate an unquestionable superiority of the FluCide drug candidate compared to current drugs, and establish it as a viable therapy against influenza. We believe that FluCide is likely the most effective drug candidate in development against influenza, based on these results.

The studies were conducted by Dr. Krishna Menon, PhD, VMD, MRCS, at KARD Scientific, MA. One million virus particles of Influenza A Strain A/WS/33 (H1N1) were aspirated directly into the lungs of mice. A repeat "booster" infection was performed at 22 hrs. This is a highly lethal model, allowing the survival lifetimes to be directly used for rank ordering of efficacy of drug candidates.

The Company has previously shown that a previous version of the FluCide drug candidate was highly effective against two different clades of the H5N1 bird flu virus, in addition to being highly effective against H1N1 in the mouse model. The Company has recently improved the FluCide drug candidate, creating what it believes to be a single drug candidate against all forms of influenza. The Company believes that the data we presented at the Influenza Conference establish this pan-influenza drug candidate as a leading anti-influenza drug in development.


About NanoViricides
We have assembled a world class team to lead us to success. We have brought together highly experienced individuals with strong expertise in their respective areas. Our team possesses the combined expertise of having performed research, development, and regulatory processing for over 25 drugs, of which 10 are approved and the rest are at various advanced clinical stages, at the team members' previous affiliations. Our team is also highly innovative, and boasts pioneering research in varied areas that are at the fore-fronts of medical science and pharmaceutical technology such as polymeric micelles, multi-specific multi-targeting, anti-sense DNA, siRNA, ribozymes, and gene therapy.

For more information, please click here


Copyright ©

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Organometallics welcomes new editor-in-chief: Paul Chirik, Ph.D. July 22nd, 2014

The Hiden EQP Plasma Diagnostic with on-board MCA July 22nd, 2014

Iran to Hold 3rd Int'l Forum on Nanotechnology Economy July 22nd, 2014

Nanometrics Announces Upcoming Investor Events July 22nd, 2014


QuantuMDx announce prototype handheld lab for 15 minute malaria diagnosis and drug resistance testing April 23rd, 2014

Nanovations Sets new Benchmark in Automotive Windscreen Coating Durability: Nanovations new automotive glass coating Vision Protect, sets new benchmark in glass coating durability March 23rd, 2014

Tawada CleanTech to show fabric duct and eco cool coating in MegaBuild March 21st, 2014

NEI Introduces Self-healing Anti-corrosion Coating for Zinc-Plated and Galvanized Steel March 14th, 2014

Possible Futures

IBM Announces $3 Billion Research Initiative to Tackle Chip Grand Challenges for Cloud and Big Data Systems: Scientists and engineers to push limits of silicon technology to 7 nanometers and below and create post-silicon future July 10th, 2014

Virus structure inspires novel understanding of onion-like carbon nanoparticles April 10th, 2014

Local girl does good March 22nd, 2014

Surface Characteristics Influence Cellular Growth on Semiconductor Material March 12th, 2014


Researchers create vaccine for dust-mite allergies Main Page Content: Vaccine reduced lung inflammation to allergens in lab and animal tests July 22nd, 2014

NIST shows ultrasonically propelled nanorods spin dizzyingly fast July 22nd, 2014

SentiMag® Now Available in Australia and New Zealand July 21st, 2014

More than glitter: Scientists explain how gold nanoparticles easily penetrate cells, making them useful for delivering drugs July 21st, 2014


Nanometrics Announces Upcoming Investor Events July 22nd, 2014

Bruker Awarded Fourth PeakForce Tapping Patent: AFM Mode Uniquely Combines Highest Resolution Imaging and Material Property Mapping July 22nd, 2014

NIST shows ultrasonically propelled nanorods spin dizzyingly fast July 22nd, 2014

Penn Study: Understanding Graphene’s Electrical Properties on an Atomic Level July 22nd, 2014


Production of Non-Virus Nanocarriers with Highest Amount of Gene Delivery July 17th, 2014

Physicists Use Computer Models to Reveal Quantum Effects in Biological Oxygen Transport: The team solved a long-standing question by explaining why oxygen – and not deadly carbon monoxide – preferably binds to the proteins that transport it around the body. July 17th, 2014

Tiny DNA pyramids enter bacteria easily -- and deliver a deadly payload July 9th, 2014

Artificial cilia: Scientists from Kiel University develop nano-structured transportation system July 4th, 2014

The latest news from around the world, FREE

  Premium Products
Only the news you want to read!
 Learn More
University Technology Transfer & Patents
 Learn More
Full-service, expert consulting
 Learn More

Nanotechnology Now Featured Books


The Hunger Project

© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE